Congleton, United Kingdom

Phillip John Morgan


Average Co-Inventor Count = 8.6

ph-index = 3

Forward Citations = 42(Granted Patents)


Company Filing History:


Years Active: 2001-2011

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Phillip John Morgan

Introduction

Phillip John Morgan, a distinguished inventor based in Congleton, GB, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of six patents, his work primarily revolves around serine protease inhibitors and angiotensin derivatives, showcasing his expertise and innovative thinking in pharmaceutical development.

Latest Patents

Among Phillip's latest patents is focused on "Meta-benzamidine derivatives as serine protease inhibitors." This invention details compounds of formula I, where the variables such as R, X, and L have specific meanings as outlined in the specification. These compounds feature either unsubstituted or substituted amidine groups and offer potential utility in inhibiting serine proteases. Another noteworthy patent he holds is for "Angiotensin derivatives," which describes a derivative that combines an angiotensin peptide moiety with a peptide carrier-binding moiety. This invention is aimed at therapeutic and prophylactic applications related to conditions connected with the renin-activated angiotensin system.

Career Highlights

Phillip's career has seen him work with prominent organizations, including Tularik Limited and Eli Lilly and Company. His tenure at these companies allowed him to refine his skills and contribute to significant pharmaceutical advancements, further establishing his reputation as an inventive force in the industry.

Collaborations

Throughout his career, Phillip has collaborated with notable colleagues, including John Walter Liebeschuetz and Christopher William Murray. These partnerships highlight the collaborative spirit inherent in the realm of scientific research and innovation, as they bring together diverse expertise to drive progress in medicinal chemistry.

Conclusion

Phillip John Morgan's innovative spirit and contributions to serine protease inhibitors and angiotensin derivatives not only exemplify his prowess as an inventor but also reflect the dynamic nature of pharmaceutical research. His work continues to pave the way for advancements in therapies that address critical health conditions, ensuring his legacy in the field of medicinal chemistry is well secured.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…